• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

    Simply Wall St·08/30/2026 11:19:52
    Listen to the news
    • In August 2026, Guardant Health said it would appeal a US District Court of Delaware final judgment in a patent dispute with TwinStrand Biosciences and the University of Washington, with execution of the judgment and collection of potential royalties paused during the appeal.
    • The court’s royalty order applies mainly to older Guardant tests, while Guardant reports that upgraded versions of key products such as Shield and Reveal, along with validated design changes to Guardant360, fall outside the current royalty scope.
    • We’ll now explore how this litigation outcome and Guardant’s claim that newer products avoid ongoing royalties may influence its investment narrative.

    AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Guardant Health Investment Narrative Recap

    To own Guardant Health, you need to believe its blood based cancer tests can grow into a large, durable business despite ongoing losses and heavy investment. Right now, the key near term catalyst is broader reimbursement and usage of tests like Shield and Guardant360, while the biggest risk is that rising costs and legal overhangs weigh on cash flow. The TwinStrand judgment adds legal and financial uncertainty, but Guardant’s claim that newer products sit outside the royalty scope may limit its practical impact near term.

    Among recent updates, the May 2026 FDA approval of Guardant360 Liquid CDx stands out here. It broadened the test’s clinical footprint and integrated genomic and epigenomic data into a single blood draw, with wide payer coverage. This kind of regulatory and commercial progress is central to the thesis that Guardant can expand oncology revenue and improve its mix, which matters even more now that legacy products are tied up in royalty and damages disputes.

    Yet while growth headlines grab attention, investors should also be aware of the unresolved patent and royalty risk that could still...

    Read the full narrative on Guardant Health (it's free!)

    Guardant Health's narrative projects $2.5 billion revenue and $3.9 million earnings by 2029.

    Uncover how Guardant Health's forecasts yield a $171.08 fair value, a 6% upside to its current price.

    Exploring Other Perspectives

    GH 1-Year Stock Price Chart
    GH 1-Year Stock Price Chart

    The most optimistic analysts were assuming revenue could reach about US$3.6 billion and earnings about US$485.0 million by 2029, yet this legal setback highlights how quickly expectations around Shield reimbursement and guideline driven growth could be tested and why your view might differ sharply from theirs.

    Explore 3 other fair value estimates on Guardant Health - why the stock might be worth just $171.08!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.